Dec 20, 2017 11:45 am UTC| Business
STAMFORD, Conn., Dec. 20, 2017 -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced...
Nodechain, Inc. Focuses on Bitcoin and Ethereum Cryptocurrency Mining
Dec 20, 2017 11:30 am UTC| Business
HUNTINGTON BEACH, Calif., Dec. 20, 2017 -- Nodechain, Inc. (OTC Pink:VPTK), ("Company" or "Nodechain, Inc"), has filed an 8K in order to reflect a change in the company's direction and overall strategy. Nodechain,...
Avivagen Inc. Announces Results for Fiscal Year Ending October 31, 2017
Dec 20, 2017 11:30 am UTC| Business
OTTAWA, Dec. 20, 2017 -- Avivagen Inc. (TSX-V:VIV) (OTC Pink:CHEXF) (“Avivagen” or the “Company”), a life sciences innovation company with a series of patent protected products that support and optimize human and animal...
WABCO Makes Strategic Investment in Advancing Electric Commercial Vehicle Sector
Dec 20, 2017 11:30 am UTC| Business
Invests $10 Million to acquire 1% equity stake in Nikola Motor CompanySigns agreement to accelerate development of industry-leading safety technologies specifically designed for electric trucks BRUSSELS, Belgium, Dec. ...
Dec 20, 2017 11:05 am UTC| Business
NEW HAVEN, Conn., Dec. 20, 2017 -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a pharmaceutical company focused on advancing small molecule inhibitors of factor D in the complement alternative pathway, today...
Petroteq Energy Subsidiary, Petrobloq, Announces Membership in Hyperledger
Dec 20, 2017 11:00 am UTC| Business
LOS ANGELES, CA, Dec. 20, 2017 -- Petroteq Energy Inc. (the “Company”) (TSXV:PQE; OTCQX: PQEFF; Frankfurt:A2DYWC), a company focused on the development and implementation of proprietary technologies, today announces...
Mesoblast’s Phase 3 Trial in Children With Acute Graft Versus Host Disease Completes Enrollment
Dec 20, 2017 11:00 am UTC| Business
NEW YORK and MELBOURNE, Australia, Dec. 20, 2017 -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that the Phase 3 trial of its proprietary allogeneic mesenchymal stem cell (MSC) product candidate MSC-100-IV...